Ricard Mesı́a
0000-0002-3785-3563
Publication & Citation Trends
Publications
0 total
Abstract CT009: IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
Cited by 12
Semantic Scholar
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Cited by 119
Semantic Scholar
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry OA
Cited by 26
Semantic Scholar
SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer OA
Cited by 6
Semantic Scholar
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
Cited by 1
Semantic Scholar
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma OA
Cited by 17
Semantic Scholar
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck OA
Cited by 13
Semantic Scholar
Research Topics
Head and Neck Cancer Studies
(188)
Lung Cancer Treatments and Mutations
(92)
Cancer Immunotherapy and Biomarkers
(70)
Cancer Diagnosis and Treatment
(42)
Head and Neck Surgical Oncology
(26)
Affiliations
Universitat Autònoma de Barcelona
Amrita Institute of Medical Sciences and Research Centre
Institut Català d'Ornitologia
Universität Hamburg
Merck (Germany)